European Medicines Company Commences Evaluation of Novel Gene Remedy Candidate Etranacogene Dezaparvovec for Individuals with Hemophilia B
Advertising and marketing Authorization Software (MAA) for etranacogene dezaparvovec might be reviewed beneath accelerated evaluation and has the potential to be the primary gene remedy for sufferers dwelling with hemophilia B MAA submitting is supported by the section 3 HOPE-B examine which demonstrated sturdy and sustained therapeutic impact after a single infusion Milestone underscores CSL…